

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

INSIDE INFORMATION

(1) DELAY IN PUBLICATION OF 2024 ANNUAL RESULTS AND DESPATCH OF ANNUAL REPORT 2024; AND (2) SUSPENSION OF TRADING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Sinopharm Tech Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 19 September 2024 and 23 September 2024 (the “**Announcements**”) in relation to, among others, (i) possible delay in publication of the 2024 Annual Results, possible postponement of the Board Meeting and possible suspension of trading; and (ii) change of auditors. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

DELAY IN PUBLICATION OF 2024 ANNUAL RESULTS AND DESPATCH OF ANNUAL REPORT 2024

Pursuant to Rule 18.49 of the GEM Listing Rules, the Company is required to publish the 2024 Annual Results not later than three months after the end of the financial year (i.e. on or before 30

September 2024). Furthermore, pursuant to Rule 18.48A and 18.03 of the GEM Listing Rules, the Company is required to publish and despatch its annual report for the year ended 30 June 2024 (the “**Annual Report 2024**”) to the Shareholders no later than four months after the end of the financial year (i.e. on or before 31 October 2024).

The Board wishes to inform the Shareholders and hereby announces that there is a delay in the publication of the 2024 Annual Results and despatch of the Annual Report 2024. As disclosed in the Announcements, due to the change of the auditors of the Group on 23 September 2024 and with reference to the audit schedule prepared by SFAI Hong Kong, it is expected that the audit procedures will be completed within November 2024. As such, the Board expects that the Company will not be able to publish the 2024 Annual Results on or before 30 September 2024. Due to the delay in the publication of the 2024 Annual Results, the Board expects that the Company will not be able to publish and despatch the Annual Report 2024 on or before 31 October 2024.

As at the date of this announcement, the Company is working closely with SFAI Hong Kong to complete the audit procedures as soon as possible. The Company will use its best endeavours to publish the 2024 Annual Results and publish and despatch the Annual Report 2024 as soon as possible but, in any event, no later than 6 December 2024. The Company will publish further announcement(s) to inform the Shareholders and potential investors of the Company of any material developments in connection with the 2024 Annual Results and the Annual Report 2024 as and when appropriate.

SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on Wednesday, 2 October 2024 pending the publication of the 2024 Annual Results.

The Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
HO Kam Kin
Executive Director

Hong Kong, 30 September 2024

As at the date of this announcement, the Board comprises Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at <https://www.hkexnews.hk> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.